Advanced Oncotherapy Balance Sheet Health
Financial Health criteria checks 2/6
Advanced Oncotherapy has a total shareholder equity of £60.5M and total debt of £24.0M, which brings its debt-to-equity ratio to 39.6%. Its total assets and total liabilities are £153.2M and £92.7M respectively.
Key information
39.6%
Debt to equity ratio
UK£23.99m
Debt
| Interest coverage ratio | n/a |
| Cash | UK£2.51m |
| Equity | UK£60.52m |
| Total liabilities | UK£92.65m |
| Total assets | UK£153.17m |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: AVO's short term assets (£32.8M) exceed its short term liabilities (£26.0M).
Long Term Liabilities: AVO's short term assets (£32.8M) do not cover its long term liabilities (£66.7M).
Debt to Equity History and Analysis
Debt Level: AVO's net debt to equity ratio (35.5%) is considered satisfactory.
Reducing Debt: AVO's debt to equity ratio has increased from 20.9% to 39.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if AVO has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if AVO has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.